人附睾蛋白4时间分辨荧光免疫分析在妇科肿瘤诊断中的价值

发布时间：2018-06-28 02:09

本文选题：子宫内膜肿瘤 + 卵巢肿瘤　；参考：《实用医学杂志》2017年05期

【摘要】：目的:建立人附睾蛋白4(HE4)时间分辨荧光免疫分析(TRFIA),探讨血清HE4检测在妇科肿瘤诊断中的价值。方法:采用铕标记示踪,构建HE4的双抗体夹心TRFIA,并检测了225例受试者血清HE4水平,分析血清HE4在妇科肿瘤中的诊断意义,并探讨诊断子宫内膜癌、卵巢癌及宫颈癌的最佳参考值。结果:HE4 TRFIA工作线性范围10~10 000 pmol/L,灵敏度7.5 pmol/L,与CA125和CA199无交叉反应,批间变异系数小于10%,与化学发光法检测结果一致。子宫内膜癌、卵巢癌及宫颈癌组的血清HE4水平明显高于健康对照组,子宫肌瘤组与健康对照组无显著差异;随年龄增长,妇科良恶性肿瘤的患病风险增加。HE4在上述恶性肿瘤检测中ROC~(AUG)0.5,运用本方法测定的参考值为60 pmol/L。结论:建立了稳定、准确的HE4 TRFIA,有助于妇科肿瘤的诊断。
[Abstract]:Objective: to establish a time resolved fluorescence immunoassay (TRFIA) for human epididymal protein 4 (HE4) and to evaluate the diagnostic value of serum HE4 in gynecological tumors. Methods: the double antibody sandwich TRFIAs of HE4 were constructed with europium labeled tracer. The serum HE4 levels were measured in 225 subjects. The diagnostic significance of serum HE4 in gynecological tumors was analyzed, and the diagnosis of endometrial carcinoma was discussed. The best reference value for ovarian cancer and cervical cancer. Results the linear range of 10 脳 10 000 pmol / L, sensitivity 7.5 pmol / L, no cross reaction with CA125 and CA199, and the coefficient of variation between batches were less than 100.Conclusion with chemiluminescence method. The serum levels of HE4 in endometrial carcinoma, ovarian cancer and cervical cancer group were significantly higher than those in healthy control group, but there was no significant difference between uterine leiomyoma group and healthy control group. The risk of gynecologic benign and malignant tumors increased. HE4 was used in the detection of above malignant tumors. The reference value measured by this method was 60 pmol / L. Conclusion: a stable and accurate HE4 TRFIA was established for the diagnosis of gynecological tumors.
【作者单位】：江苏省原子医学研究所卫生部核医学重点实验室江苏省分子核医学实验室;江苏省无锡市妇幼保健院;江苏省江阴市人民医院;
【基金】：江苏省卫生计生委科研课题(编号:H201637) 江苏省社会发展基金项目(编号:BE2009631)
【分类号】：R737.3

【相似文献】